Revance Therapeutics (RVNC) 10-Q 3 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 26, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Central Index Key	1,479,290
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		30,934,688

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 56,323	$ 63,502
Short-term investments	97,117	122,026
Prepaid expenses and other current assets	2,827	7,167
Total current assets	156,267	192,695
Property and equipment, net	11,500	10,585
Restricted cash	580	580
Other non-current assets	836	500
TOTAL ASSETS	169,183	204,360
CURRENT LIABILITIES
Accounts payable	6,680	3,754
Accruals and other current liabilities	12,069	12,418
Financing obligations, current portion	2,727	3,475
Total current liabilities	21,476	19,647
Financing obligations, net of current portion	0	1,872
Derivative liability associated with Medicis settlement	2,233	2,022
Deferred rent	3,418	3,648
Other non-current liabilities	0	100
TOTAL LIABILITIES	27,127	27,289
Commitments and Contingencies (Note 10)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.001 per share — 95,000,000 shares authorized as of September 30, 2017 and December 31, 2016; 30,935,094 and 28,648,954 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	31	29
Additional paid-in capital	648,329	598,630
Accumulated other comprehensive loss	(43)	(45)
Accumulated deficit	(506,261)	(421,543)
TOTAL STOCKHOLDERS’ EQUITY	142,056	177,071
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 169,183	$ 204,360

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	95,000,000	95,000,000
Common stock, shares issued (in shares)	30,935,094	28,648,954
Common stock, shares outstanding (in shares)	30,935,094	28,648,954

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue	$ 75	$ 75	$ 225	$ 225
Operating expenses:
Research and development	21,643	10,296	59,357	37,851
General and administrative	9,148	7,502	25,511	21,975
Loss on impairment	0	0	0	1,949
Total operating expenses	30,791	17,798	84,868	61,775
Loss from operations	(30,716)	(17,723)	(84,643)	(61,550)
Interest income	341	306	999	940
Interest expense	(104)	(256)	(439)	(857)
Change in fair value of derivative liability associated with Medicis settlement	(44)	(167)	(211)	(595)
Other expense, net	(128)	(138)	(386)	(406)
Net loss	(30,651)	(17,978)	(84,680)	(62,468)
Unrealized gain (loss) on available for sale securities	72	(132)	3	56
Comprehensive loss	(30,579)	(18,110)	(84,677)	(62,412)
Net loss attributable to common stockholders:
Net loss attributable to common stockholders, basic and diluted	$ (30,651)	$ (17,978)	$ (84,680)	$ (62,468)
Net loss per share attributable to common stockholders (Note 12):
Basic and Diluted (in USD per share)	$ (1.01)	$ (0.64)	$ (2.86)	$ (2.22)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic and Diluted (in shares)	30,270,260	28,160,458	29,623,805	28,085,541

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (84,680)	$ (62,468)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,096	1,068
Amortization of premium on investment	382	1,029
Change in fair value of derivative liability associated with Medicis settlement	211	595
Stock-based compensation expense	9,820	8,984
Capitalized interest	(37)	0
Effective interest on financing obligations	217	315
Loss on impairment	0	1,949
Acquisition of in-process research and development	0	2,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	4,632	(5,852)
Other non-current assets	(488)	0
Accounts payable	2,749	200
Accruals and other liabilities	(848)	5,821
Net cash used in operating activities	(66,946)	(46,359)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,037)	(1,152)
Proceeds from maturities of investments	60,655	139,050
Proceeds from sales of investments	0	1,000
Purchases of investments	(36,028)	(159,754)
Payment for acquisition of in-process research and development	(100)	(1,800)
Net cash provided by (used in) investing activities	22,490	(22,656)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of at-the-market offering commissions	38,760	0
Principal payments made on financing obligations	(2,727)	(2,622)
Net settlement of restricted stock awards to settle employee taxes	(430)	(359)
Proceeds from the exercise of stock options and employee stock purchase plan	2,116	1,250
Payment of registration statement and at-the-market offering costs	(441)	(243)
Net cash provided by financing activities	37,278	(1,974)
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(7,178)	(70,989)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	64,082	202,050
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	56,904	131,061
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	259	542
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals and other current liabilities	429	29
Deferred at-the-market offering costs	11	0
Holdback related to acquisition of in-process research and development	$ 0	$ 200

The Company and Basis of Presen

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation Revance Therapeutics, Inc., or the Company, was incorporated in Delaware on August 10, 1999 under the name Essentia Biosystems, Inc. The Company commenced operations in June 2002 and on April 19, 2005 , changed its name to Revance Therapeutics, Inc. The Company is a clinical-stage biotechnology company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The Company is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide technology, to address unmet needs in large and growing neurotoxin markets. The Company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The Company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications and is planning to conduct additional preclinical development for RT001 topical. The Company holds worldwide rights to RT002 injectable, RT001 topical and the pharmaceutical uses of its proprietary peptide technology. Since commencing operations in 2002, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetics and therapeutic pharmaceutical markets, recruiting personnel and raising capital, and preclinical and clinical development of, and manufacturing development for, RT002 injectable and RT001 topical. The Company has never been profitable and has not yet commenced commercial operations. Since inception, the Company has incurred losses and negative cash flows from operations. The Company has not generated significant revenue from product sales to date and will continue to incur significant research and development and other expenses related to its ongoing operations. During the nine months ended September 30, 2017 , the Company had a net loss of $84.7 million and used $66.9 million of cash for operating activities. As of September 30, 2017 , the Company had a working capital surplus of $134.8 million and an accumulated deficit of $506.3 million . The Company has funded its operations since inception primarily through the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2017 , the Company had capital resources consisting of cash, cash equivalents, and investments of $153.4 million . The Company believes that its existing cash, cash equivalents and investments will allow the Company to fund its operations through at least the next 12 months following the filing of this Form 10-Q. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Statements of Operations and Comprehensive Loss and Condensed Consolidated Statements of Cash Flows for the interim periods covered and the Condensed Consolidated Balance Sheets at the date of the balance sheets. The Condensed Consolidated Balance Sheet for the year ended December 31, 2016 was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or US GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2017 , or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 , which was filed with the Securities and Exchange Commission, or SEC, on February 28, 2017. The Condensed Consolidated Financial Statements of the Company include the Company’s accounts and those of the Company’s wholly-owned subsidiary and have been prepared in conformity with US GAAP. The Company operates in one segment and there were no intercompany transactions to be eliminated during consolidation. At-The-Market Offering In March 2016, the Company entered into an At-The-Market Issuance Sales Agreement, or the 2016 ATM agreement, with Cowen and Company, LLC, or Cowen, under which the Company may offer and sell common stock having aggregate proceeds of up to $75.0 million from time to time through Cowen, the Company's sales agent. Sales of common stock through Cowen under the 2016 ATM agreement will be made by means of ordinary brokers’ transactions on the NASDAQ Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cowen. Cowen will sell the common stock from time to time, based upon instructions from the Company. The Company agreed to pay Cowen a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM agreement. During three months ended September 30, 2017, the Company sold 389,600 shares of its common stock primarily to one investor under the 2016 ATM agreement at a price of $25.56 per share resulting in net proceeds of $9.6 million , after commissions and offering expenses. During the nine months ended September 30, 2017, the Company sold 1,802,651 shares of common stock under the 2016 ATM Agreement at a weighted average price of $22.17 per share resulting in net proceeds of $38.2 million , which was comprised of gross proceeds after commissions of $38.8 million net of offering expenses of $0.6 million , of which $0.2 million was paid in 2016 and $0.4 million was paid in 2017.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Significant accounting policies are described in Note 2 to the Consolidated Financial Statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . There have been no changes to the Company’s significant accounting policies during the nine months ended September 30, 2017 , except as described below. Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of a derivative liability, impairment of long-lived assets, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates. Recently Adopted Accounting Pronouncements On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statements of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. As of January 1, 2017, the Company adopted ASU 2016-09 on a modified retrospective basis for the income statement impact of forfeitures and income taxes. Accordingly, the Company recognized a cumulative charge of less than $0.1 million to the Company's Accumulated Deficit balance as of January 1, 2017 from a change in the forfeiture rate methodology to account for forfeitures as they occur. The Company also adopted the accounting methodology related to stock-based compensation for deferred tax assets and liabilities balances; however, given the Company has a full valuation allowance, it did not have a material impact on the Company's Consolidated Financial Statements. The new guidance had no impact to classification on the Condensed Consolidated Statements of Cash Flows. On November 18, 2016, the FASB issued Accounting Standards Update (ASU) 2016-18, Statements of Cash Flows (Topic 230) , which requires restricted cash to be included in the beginning-of-period and end-of-period totals with cash and cash equivalents. The Company early adopted this amendment as of December 31, 2016. The adoption of this standard required the Company to reclassify its restricted cash balances from investing activities to the cash and cash equivalents section of the Condensed Consolidated Statements of Cash Flows for all periods presented. Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting (Topic 718) ("ASU 2017-09"), which amends the scope of modification accounting for share-based payment arrangements. The amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments in ASU 2016-16 are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods and requires a modified retrospective method of adoption. Early adoption is permitted, but for public companies generally only in the first quarter of an entity’s annual fiscal year. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. On February 25, 2016, the FASB issued Accounting Standards Update (ASU) 2016-02 Leases (Topic 842) which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases with terms greater than 12 months. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which provides additional implementation guidance on the previously issued ASU 2016-02 Leases (Topic 842) . The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. On January 5, 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The updated standard is effective for fiscal years, and interim periods, beginning after December 15, 2017 and early adoption is not permitted. The Company is currently evaluating the impact that the standard will have on its Consolidated Financial Statements.

In-Process Research and Develop

In-Process Research and Development	9 Months Ended
	Sep. 30, 2017
Research and Development [Abstract]
In-Process Research and Development	In-Process Research and Development On June 2, 2016, the Company entered into an asset purchase agreement with Botulinum Toxin Research Associates, Inc., or BTRX (the "BTRX Purchase Agreement"). Under the BTRX Purchase Agreement, the Company acquired all rights, title and interest in a portfolio of botulinum toxin-related patents and patent applications from BTRX and was granted the right of first negotiation and first refusal with respect to other botulinum toxin-related patents owned or controlled by BTRX. In exchange, the Company agreed to an upfront expenditure of $2.0 million of which $1.8 million was paid immediately, $0.1 million was paid in June 2017, and the remaining $0.1 million is due and payable in June 2018. The Company also agreed to pay up to an additional $16.0 million in aggregate upon satisfaction of specified milestones relating to the Company’s product revenue, intellectual property, and clinical and regulatory events (the "BTRX milestone payments"). As of September 30, 2017, the Company did not record a liability in connection with the BTRX milestone payments. The Company accrues for contractual milestones when it is probable that a milestone will be met. The Company concluded that the BTRX Purchase Agreement did not meet the criteria of a business combination pursuant to the guidance prescribed in Accounting Standards Codification Topic 805, Business Combinations . During 2016, the Company accounted for the initial $2.0 million expenditure as research and development expense, as future alternative use of the acquired assets was deemed contingent upon the successful outcome of existing research and development activities as of the transaction date.

Medicis Settlement

Medicis Settlement	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Medicis Settlement	Medicis Settlement In July 2009, the Company entered into a license agreement with Medicis Pharmaceutical Corporation, or Medicis, granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidates. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million , comprised of (i) an upfront payment of $7.0 million , which was paid in 2012, (ii) a proceeds sharing arrangement payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and $7.1 million in 2014, and (iii) a Product Approval Payment of $4.0 million to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. As of September 30, 2017 , the Company determined the fair value of its liability for the Product Approval Payment was $2.2 million , which was measured by assuming a term of 2.75 years, a risk-free rate of 1.58% and a credit risk adjustment of 7.00% . The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during the nine months ended September 30, 2017 .

Cash Equivalents and Investment

Cash Equivalents and Investments	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Investments	Cash Equivalents and Investments The Company's cash equivalents and investments consist of money market funds, U.S. treasury securities, and U.S. government agency obligations, which are classified as available-for-sale securities. The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands): September 30, 2017 December 31, 2016 Gross Unrealized Gross Unrealized Cost Gains Losses Fair Value Cost Gains Losses Fair Value Money market funds $ 55,480 $ — $ — $ 55,480 $ 60,639 $ — $ — $ 60,639 U.S. treasury securities 81,210 — (35 ) 81,175 81,103 4 (28 ) 81,079 U.S. government agency obligations 15,950 — (8 ) 15,942 40,968 1 (22 ) 40,947 Total cash equivalents and available-for-sale securities $ 152,640 $ — $ (43 ) $ 152,597 $ 182,710 $ 5 $ (50 ) $ 182,665 Classified as: Cash equivalents $ 55,480 $ 60,639 Short-term investments 97,117 122,026 Total cash equivalents and available-for-sale securities $ 152,597 $ 182,665 There have been no significant realized gains or losses on available-for-sale securities for the periods presented. No significant available-for-sale securities held as of September 30, 2017 have been in a continuous unrealized loss position for more than 12 months, and unrealized gains and losses are included in “accumulated other comprehensive loss” within shareholders’ equity on the Condensed Consolidated Balance Sheets. As of September 30, 2017 , unrealized losses on available-for-sale investments are not attributed to credit risk and are considered temporary. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the cost basis of the investment will be recovered. The Company believes it has no other-than-temporary impairments on its securities as it does not intend to sell these securities and does not believe it is more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in fair value. Our cash equivalents and short-term investments are due within one year. Related Party Transactions Of the Company's total cash, cash equivalents, and short-term investments of $153.4 million and $185.5 million as of September 30, 2017 and December 31, 2016, respectively, the Company held cash equivalents and short-term investments with a total fair value of $75.4 million and $86.0 million , respectively, in an investment account with a related party, J.P. Morgan Securities LLC. As of September 30, 2017 , JPMorgan Chase & Co. and its wholly owned subsidiaries JPMorgan Chase Bank, National Association (NA), J.P. Morgan Investment Management Inc., and JPMorgan Asset Management (UK) Limited held approximately 3.5 million shares of the Company's common stock, which represents approximately 11.4% of the Company's outstanding common stock. J.P. Morgan Securities LLC, who acts as a custodian and trustee for certain Company investments, is an affiliate of JPMorgan Chase Bank, NA.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company determines the fair value of certain financial assets and liabilities using three levels of inputs as follows: • Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances. The carrying values of cash, prepaid expenses and other current assets, accounts payable, and accruals and other current liabilities approximate fair value due to the short maturities of these instruments. The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows (in thousands): As of September 30, 2017 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 55,480 $ 55,480 $ — $ — U.S. treasury securities 81,175 81,175 — — U.S. government agency obligations 15,942 — 15,942 — Total assets measured at fair value $ 152,597 $ 136,655 $ 15,942 $ — Liabilities Derivative liability associated with Medicis settlement $ 2,233 $ — $ — $ 2,233 Total liabilities measured at fair value $ 2,233 $ — $ — $ 2,233 As of December 31, 2016 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 60,639 $ 60,639 $ — $ — U.S. treasury securities 81,079 81,079 — — U.S. government agency obligations 40,947 — 40,947 — Total assets measured at fair value $ 182,665 $ 141,718 $ 40,947 $ — Liabilities Derivative liabilities associated with Medicis settlement $ 2,022 $ — $ — $ 2,022 Total liabilities measured at fair value $ 2,022 $ — $ — $ 2,022 The fair value of the U.S. government agency obligations is estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between Level 1 and Level 2 during the nine months ended September 30, 2017 and the year ended December 31, 2016 . The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands): Derivative Liability Associated with Medicis Settlement Fair value as of December 31, 2016 $ 2,022 Change in fair value 211 Fair value as of September 30, 2017 $ 2,233 The fair value of the derivative liability resulting from the Medicis litigation settlement was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (Note 4). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the Product Approval Payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.

Notes Payable and Financing Obl

Notes Payable and Financing Obligations	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Notes Payable and Financing Obligations	Notes Payable and Financing Obligations Essex Capital Notes On December 20, 2013, the Company signed a Loan and Lease Agreement (Original Agreement) to borrow up to $10.8 million in the form of Secured Promissory Notes from Essex Capital, or the Essex Notes, to finance the completion and installation of the Company’s RT001 topical commercial fill/finish line, or the Fill/Finish Line. In December 2013 and January 2014, the Company withdrew a total of $5.0 million under the terms of the Original Agreement. In May 2014, pursuant to the terms of the Original Agreement, the Company sold equipment to Essex Capital, resulting in partial settlement of the outstanding loan balance of $1.1 million , and leased the equipment back for fixed monthly payments to be paid over 3 years. On December 17, 2014, the Company entered into the First Amendment to the Loan and Lease Agreement (First Amendment) with Essex Capital. Under the terms of the First Amendment, the Company agreed to repay the outstanding debt balance of $3.9 million and issued a warrant to purchase 44,753 shares of common stock. In February 2015, the Company executed the Second Amendment to the Loan and Lease Agreement (Second Amendment), under which the term of the facility was extended to April 15, 2015 and the purchase price for the remainder of the equipment was increased by $0.1 million to approximately $9.8 million . Concurrently with this sale, the Company leased the equipment back from Essex Capital for a fixed monthly payment to be paid monthly over 3 years. None of the leases qualified for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for these transactions as financing obligations using the effective interest rate method. The leases provide for the option to purchase the leased equipment for 10% of the original purchase amount and, in June 2015, the Company exercised its option to purchase the remainder of the equipment sold and leased back from Essex Capital for 10% of the original purchase amount, or approximately $1.1 million , at the conclusion of the lease terms. In May 2017, the Company paid $0.1 million to purchase the equipment sold and leased back from Essex Capital in May 2014. As of September 30, 2017 , the aggregate total future minimum lease payments under the financing obligations were as follows (in thousands): Year Ending December 31, 2017 $ 948 2018 949 Total payments $ 1,897

Interest Expense

Interest Expense	9 Months Ended
	Sep. 30, 2017
Other Income and Expenses [Abstract]
Interest Expense	Interest Expense Interest expense, includes cash and non-cash components with the non-cash components consisting of effective interest recognized on the financing obligations and interest capitalized for assets constructed for use in operations. The interest expense by cash and non-cash components is as follows (in thousands): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Interest expense Cash related interest expense (1) $ 63 $ 158 $ 259 $ 542 Non-cash interest expense Effective interest on financing obligations 62 98 217 315 Non-cash capitalized interest expense (2) (21 ) — (37 ) — Non-cash interest expense 41 98 180 315 Total interest expense $ 104 $ 256 $ 439 $ 857 (1) Cash related interest expense includes interest payments on the Essex Notes. (2) Capitalized interest expense pursuant to Accounting Standards Codification Topic 835, Interest .

Loss on Impairment

Loss on Impairment	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Loss on Impairment	Loss on Impairment Long-lived assets such as the Company’s fill/finish line are reviewed for impairment whenever adverse events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets are measured by a comparison of the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company determines the fair value of its long-lived assets using the market, cost or income approach. The Company constructed a fill/finish line for the future commercial manufacturing of RT001 topical and to support its clinical trials and regulatory license applications. In June 2016, following the results of the REALISE 1 Phase 3 clinical trial, the Company discontinued its RT001 topical clinical development programs for the treatment of crow’s feet and primary axillary hyperhidrosis. The Company performed an impairment analysis of the RT001 topical fill/finish line to determine fair value based on highest and best use. Based on the analysis, the Company determined that the fair value of certain equipment, which was calculated using the market approach, was lower than the carrying value. Accordingly, during the nine months ended September 30, 2016, the Company recorded a loss on impairment of $1.9 million . During the three and nine months ended September 30, 2017 , there were no additional indicators of or loss on impairment recorded for the RT001 topical fill/finish line. Nonetheless, it is reasonably possible that our estimate of the recoverability of the equipment's carrying value could change. As of September 30, 2017 , the fill/finish line had a net book value of $5.1 million .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Facility Lease In January 2010, the Company entered into a non-cancelable facility lease that requires monthly payments through January 2022. This facility is used for research, manufacturing, and administrative functions. In February 2014, the Company extended the term of the Lease by thirty-six ( 36 ) months to January 2025. Under the terms of the lease agreement, the payments escalate over the term of the lease with the exception of a decrease in payments at the beginning of 2022. However, the Company recognizes the expense on a straight-line basis over the life of the lease. Rent expense was $1.3 million for the three months ended September 30, 2017 and 2016 , respectively, and $4.0 million for the nine-month periods ended September 30, 2017 and 2016, respectively. As of September 30, 2017 , the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands): Year Ending December 31, 2017 $ 1,350 2018 5,578 2019 5,763 2020 5,947 2021 and thereafter 20,644 Total payments $ 39,282 Other Milestone-Based Commitments The Company has one remaining future milestone payment to List Laboratories due and payable on the achievement of a certain regulatory milestone. The Company is also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. The Company has one remaining future milestone payment of $4.0 million due and payable to Valeant Pharmaceuticals International, Inc., which acquired Medicis in December 2012, upon the achievement of regulatory approval for RT002 injectable or RT001 topical (Note 4). The Company has obligations to pay Botulinum Toxin Research Associates, Inc. (BTRX) up to $16.0 million upon the satisfaction of specified milestones relating to the Company’s product revenue, intellectual property, and clinical and regulatory events (Note 3). In April 2016, the Company entered into an agreement with BioSentinel, Inc. to in-license their technology and expertise for research and development and manufacturing purposes. In addition to minimum quarterly use fees, the Company has a one-time future milestone payment of $0.3 million payable to BioSentinel, Inc. upon the achievement of regulatory approval. The Company accrues for contingencies when it is probable that a loss has been incurred and the amount of loss can be reasonably estimated. The Company expects that contingencies related to regulatory approval milestones will only become probable once such regulatory outcome is achieved. Purchase Commitments On March 14, 2017, the Company entered into a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Services Agreement”) and Statement of Work ("SoW") with Ajinomoto Althea, Inc., a contract development and manufacturing organization (“Althea”). Under the Services Agreement, Althea has agreed, among other things, to provide the Company with a future source of commercial fill/finish services for the Company’s neuromodulator products. The Services Agreement has an initial term that will expire in 2024, unless terminated sooner by either party. In accordance with the Services Agreement, the Company will have minimum purchase obligations based on its production forecasts. As of September 30, 2017, the Company made non-refundable advanced payments of $1.2 million in accordance with the terms of this arrangement. The remaining services are cancellable at any time, with the Company required to pay costs incurred through the cancellation date. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. During the period from May 2015 through July 2017, the Company and certain of its directors and executive officers were subject to a securities class action complaint, pending in the Superior Court for the County of Santa Clara, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al. , Case No. 15-CV-287794 (previously assigned Case No. CIV 533635 prior to transfer from San Mateo Superior Court). On October 31, 2016, the parties executed a stipulation of settlement (the "Stipulation"), pursuant to which, in exchange for a release of all claims by the plaintiff class, the Company agreed to settle the litigation for $6.4 million in cash, of which $5.9 million was covered by its insurance policies. The Stipulation maintains that the defendants, including the Company, deny all wrongdoing and liability related to the litigation. On July 28, 2017, the Court granted final approval of the Settlement, as set forth in the Stipulation, and entered a Judgment dismissing the action with prejudice, thereby ending the litigation. This litigation did not have a material adverse effect on our business, results of operations, financial position or cash flows. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As a result of the Settlement, as set forth in the Stipulation, the Company began accruing for a loss contingency and recorded an undiscounted liability of $6.4 million in October 2016, which was included in accruals and other current liabilities on the Consolidated Balance Sheet until it was released upon the final approval of the Settlement on July 28, 2017. In January 2017, the Company paid $0.5 million , which was recorded in restricted cash on the Condensed Consolidated Balance Sheet until it was released, and its insurance company paid $5.9 million , which was recorded in prepaid and other current assets on the Condensed Consolidated Balance Sheet until it was released, both of which were held in an escrow account until final approval of the Settlement on July 28, 2017, when they were paid to the plaintiff. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded to date, except as noted above.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Convertible Preferred Stock As of September 30, 2017 and December 31, 2016, the Company had 5,000,000 shares of convertible preferred stock with a par value of $0.001 per share authorized and no preferred stock issued and outstanding. Warrants As of September 30, 2017 and December 31, 2016 , the Company had outstanding warrants to purchase 41,595 and 61,595 shares of common stock, respectively. In July 2017, a warrant to purchase 20,000 shares of common stock was net exercised by Essex Capital for 9,388 shares of common stock at an exercise price per share of $14.40 in accordance with the terms of the warrant agreement. Stock Option Plan 2014 Equity Incentive Plan and 2014 Inducement Plan On January 1, 2017, the number of shares of common stock reserved for issuance under the Company’s 2014 Equity Incentive Plan, or 2014 EIP, automatically increased by 4% of the total number of shares of the Company’s common stock outstanding on December 31, 2016, or 1,145,958 shares. During the nine months ended September 30, 2017 , the Company granted stock options for 868,625 shares of common stock and 310,575 restricted stock awards under the 2014 EIP. As of September 30, 2017 , there were 911,380 shares available for issuance under the 2014 EIP. During the nine months ended September 30, 2017 , the Company granted stock options for 35,000 shares of common stock and 95,000 restricted stock awards granted under the 2014 Inducement Plan (the "2014 IN"). As of September 30, 2017 , there were 288,867 shares available for issuance under the 2014 IN. The grant-date fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 6.0 6.0 6.0 6.0 Expected volatility 66.6 % 64.2 % 67.8 % 61.6 % Risk-free interest rate 2.0 % 1.2 % 2.1 % 1.4 % Expected dividend rate — % — % — % — % Fair Value of Common Stock . The fair value of the shares of common stock is based on the Company's stock price as quoted by the NASDAQ. Expected Term . The expected term for employees and non-employee directors is based on the simplified method, as the Company’s stock options have the following characteristics: (i) granted at-the-money; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable, or “plain vanilla” options, and the Company has a limited history of exercise data. The expected term for non-employee consultants is based on the remaining contractual term. Expected Volatility . As of January 1, 2017, the expected volatility is based on the historical volatility of a group of similar entities combined with the historical volatility of the Company, whereas prior to 2017, the expected volatility was based solely on the historical volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. Risk-Free Interest Rate . The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term of the options. Expected Dividend Rate . The Company has not and does not plan to pay dividends in the foreseeable future, and therefore used an expected dividend rate of zero percent in the valuation model. Forfeitures. As of January 1, 2017, the Company adopted the forfeiture rate methodology change in accordance with ASC 2016-09 to account for forfeitures as they occur (Note 2). Prior to the adoption of ASC 2016-09, the Company was required to estimate forfeitures at the time of grant and revised those estimates in subsequent periods if actual forfeitures differed from those estimates. The Company used historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that were expected to vest. To the extent actual forfeitures differed from the estimates, the difference was recorded as a cumulative adjustment in the period that the estimates were revised. In June 2017, an employee converted to a non-employee consultant and the individual's options and awards continued to vest in accordance with the 2014 EIP. There were no stock option grants made to non-employee consultants during 2017. The fair value of the stock options outstanding for non-employee consultants is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 8.9 7.2 8.9 7.5 Expected volatility 68.1 % 66.5 % 68.6 % 69.7 % Risk-free interest rate 2.2 % 1.4 % 2.2 % 1.5 % Expected dividend rate — % — % — % — % 2014 Employee Stock Purchase Plan On January 1, 2017, the number of shares of common stock reserved for issuance under the Company’s 2014 Employee Stock Purchase Plan, or 2014 ESPP, automatically increased by 1% of the total number of shares of the Company’s common stock outstanding on December 31, 2016 , or 286,489 shares. As of September 30, 2017 , there were 931,181 shares available for issuance under the 2014 ESPP. The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 0.5 0.5 0.5 0.5 Expected volatility 46.6 % 80.9 % 59.1 % 72.0 % Risk-free interest rate 1.1 % 0.4 % 0.9 % 0.4 % Expected dividend rate — % — % — % — % Fair Value of Common Stock . The fair value of the shares of common stock is based on the Company’s stock price. Expected Term . The expected term is based on the term of the purchase period under the 2014 ESPP. Expected Volatility . As of January 1, 2017 the expected volatility is based on the historical volatility of the Company's common stock. Prior to January 1, 2017, the expected volatility was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. Risk-Free Interest Rate . The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term. Expected Dividend Rate . The Company has never paid dividends and does not plan to pay dividends in the foreseeable future, and therefore used an expected dividend rate of zero percent in the valuation model. Total Stock-Based Compensation Total stock-based compensation expense related to options, restricted stock awards, and ESPP for employees, non-employee directors, and non-employee consultants was allocated as follows (in thousands): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Research and development $ 1,534 $ 1,124 $ 4,341 $ 4,325 General and administrative 1,612 1,631 5,479 4,659 Total stock-based compensation expense $ 3,146 $ 2,755 $ 9,820 $ 8,984

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2017 and 2016 (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net loss attributable to common stockholders, basic and diluted $ (30,651 ) $ (17,978 ) $ (84,680 ) $ (62,468 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.01 ) $ (0.64 ) $ (2.86 ) $ (2.22 ) Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 30,270,260 28,160,458 29,623,805 28,085,541 The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented as their inclusion would have been antidilutive: As of September 30, 2017 2016 Outstanding common stock options 3,381,927 2,843,580 Outstanding common stock warrants 41,595 61,595 Unvested restricted stock awards 640,931 327,899 Shares expected to be purchased on December 31 under the 2014 ESPP 14,778 11,643

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event In October 2017, the Company created a wholly owned subsidiary, Revance International Limited, which is incorporated in the Cayman Islands, and is transferring the economic rights to certain intellectual property for approximately $42 million to the newly formed subsidiary. The transaction had no financial statement impact to the Company other than to decrease the current net operating loss by the amount of the consideration.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of a derivative liability, impairment of long-lived assets, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.
Accounting Pronouncements	Recently Adopted Accounting Pronouncements On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statements of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. As of January 1, 2017, the Company adopted ASU 2016-09 on a modified retrospective basis for the income statement impact of forfeitures and income taxes. Accordingly, the Company recognized a cumulative charge of less than $0.1 million to the Company's Accumulated Deficit balance as of January 1, 2017 from a change in the forfeiture rate methodology to account for forfeitures as they occur. The Company also adopted the accounting methodology related to stock-based compensation for deferred tax assets and liabilities balances; however, given the Company has a full valuation allowance, it did not have a material impact on the Company's Consolidated Financial Statements. The new guidance had no impact to classification on the Condensed Consolidated Statements of Cash Flows. On November 18, 2016, the FASB issued Accounting Standards Update (ASU) 2016-18, Statements of Cash Flows (Topic 230) , which requires restricted cash to be included in the beginning-of-period and end-of-period totals with cash and cash equivalents. The Company early adopted this amendment as of December 31, 2016. The adoption of this standard required the Company to reclassify its restricted cash balances from investing activities to the cash and cash equivalents section of the Condensed Consolidated Statements of Cash Flows for all periods presented. Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting (Topic 718) ("ASU 2017-09"), which amends the scope of modification accounting for share-based payment arrangements. The amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments in ASU 2016-16 are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods and requires a modified retrospective method of adoption. Early adoption is permitted, but for public companies generally only in the first quarter of an entity’s annual fiscal year. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. On February 25, 2016, the FASB issued Accounting Standards Update (ASU) 2016-02 Leases (Topic 842) which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases with terms greater than 12 months. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which provides additional implementation guidance on the previously issued ASU 2016-02 Leases (Topic 842) . The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements. On January 5, 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The updated standard is effective for fiscal years, and interim periods, beginning after December 15, 2017 and early adoption is not permitted. The Company is currently evaluating the impact that the standard will have on its Consolidated Financial Statements.

Cash Equivalents and Investme20

Cash Equivalents and Investments (Tables)	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands): September 30, 2017 December 31, 2016 Gross Unrealized Gross Unrealized Cost Gains Losses Fair Value Cost Gains Losses Fair Value Money market funds $ 55,480 $ — $ — $ 55,480 $ 60,639 $ — $ — $ 60,639 U.S. treasury securities 81,210 — (35 ) 81,175 81,103 4 (28 ) 81,079 U.S. government agency obligations 15,950 — (8 ) 15,942 40,968 1 (22 ) 40,947 Total cash equivalents and available-for-sale securities $ 152,640 $ — $ (43 ) $ 152,597 $ 182,710 $ 5 $ (50 ) $ 182,665 Classified as: Cash equivalents $ 55,480 $ 60,639 Short-term investments 97,117 122,026 Total cash equivalents and available-for-sale securities $ 152,597 $ 182,665

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The fair value of these instruments was as follows (in thousands): As of September 30, 2017 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 55,480 $ 55,480 $ — $ — U.S. treasury securities 81,175 81,175 — — U.S. government agency obligations 15,942 — 15,942 — Total assets measured at fair value $ 152,597 $ 136,655 $ 15,942 $ — Liabilities Derivative liability associated with Medicis settlement $ 2,233 $ — $ — $ 2,233 Total liabilities measured at fair value $ 2,233 $ — $ — $ 2,233 As of December 31, 2016 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 60,639 $ 60,639 $ — $ — U.S. treasury securities 81,079 81,079 — — U.S. government agency obligations 40,947 — 40,947 — Total assets measured at fair value $ 182,665 $ 141,718 $ 40,947 $ — Liabilities Derivative liabilities associated with Medicis settlement $ 2,022 $ — $ — $ 2,022 Total liabilities measured at fair value $ 2,022 $ — $ — $ 2,022
Summary of Changes in Fair Value of Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands): Derivative Liability Associated with Medicis Settlement Fair value as of December 31, 2016 $ 2,022 Change in fair value 211 Fair value as of September 30, 2017 $ 2,233

Notes Payable and Financing O22

Notes Payable and Financing Obligations (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation	As of September 30, 2017 , the aggregate total future minimum lease payments under the financing obligations were as follows (in thousands): Year Ending December 31, 2017 $ 948 2018 949 Total payments $ 1,897

Interest Expense (Tables)

Interest Expense (Tables)	9 Months Ended
	Sep. 30, 2017
Other Income and Expenses [Abstract]
Summary of Interest Expense by Cash and Non-Cash Components	The interest expense by cash and non-cash components is as follows (in thousands): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Interest expense Cash related interest expense (1) $ 63 $ 158 $ 259 $ 542 Non-cash interest expense Effective interest on financing obligations 62 98 217 315 Non-cash capitalized interest expense (2) (21 ) — (37 ) — Non-cash interest expense 41 98 180 315 Total interest expense $ 104 $ 256 $ 439 $ 857 (1) Cash related interest expense includes interest payments on the Essex Notes. (2) Capitalized interest expense pursuant to Accounting Standards Codification Topic 835, Interest .

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases	As of September 30, 2017 , the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands): Year Ending December 31, 2017 $ 1,350 2018 5,578 2019 5,763 2020 5,947 2021 and thereafter 20,644 Total payments $ 39,282

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Stock-based Compensation Expense	Total stock-based compensation expense related to options, restricted stock awards, and ESPP for employees, non-employee directors, and non-employee consultants was allocated as follows (in thousands): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Research and development $ 1,534 $ 1,124 $ 4,341 $ 4,325 General and administrative 1,612 1,631 5,479 4,659 Total stock-based compensation expense $ 3,146 $ 2,755 $ 9,820 $ 8,984
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions	The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 0.5 0.5 0.5 0.5 Expected volatility 46.6 % 80.9 % 59.1 % 72.0 % Risk-free interest rate 1.1 % 0.4 % 0.9 % 0.4 % Expected dividend rate — % — % — % — %
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions	The grant-date fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 6.0 6.0 6.0 6.0 Expected volatility 66.6 % 64.2 % 67.8 % 61.6 % Risk-free interest rate 2.0 % 1.2 % 2.1 % 1.4 % Expected dividend rate — % — % — % — %
Non-employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions	The fair value of the stock options outstanding for non-employee consultants is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended 2017 2016 2017 2016 Expected term (in years) 8.9 7.2 8.9 7.5 Expected volatility 68.1 % 66.5 % 68.6 % 69.7 % Risk-free interest rate 2.2 % 1.4 % 2.2 % 1.5 % Expected dividend rate — % — % — % — %

Net Loss per Share Attributab26

Net Loss per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2017 and 2016 (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net loss attributable to common stockholders, basic and diluted $ (30,651 ) $ (17,978 ) $ (84,680 ) $ (62,468 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.01 ) $ (0.64 ) $ (2.86 ) $ (2.22 ) Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 30,270,260 28,160,458 29,623,805 28,085,541
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented as their inclusion would have been antidilutive: As of September 30, 2017 2016 Outstanding common stock options 3,381,927 2,843,580 Outstanding common stock warrants 41,595 61,595 Unvested restricted stock awards 640,931 327,899 Shares expected to be purchased on December 31 under the 2014 ESPP 14,778 11,643

The Company and Basis of Pres27

The Company and Basis of Presentation - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from issuance of common stock, net of at-the-market offering commissions				$ 38,760,000	$ 0
Company's incorporation date				Aug. 10, 1999
Commencement date of operations				Jun. 30, 2002
Change of entity name date				Apr. 19, 2005
Net loss		$ 30,651,000	$ 17,978,000	$ 84,680,000	62,468,000
Net cash used in operating activities				66,946,000	$ 46,359,000
Working capital surplus		134,800,000		134,800,000
Accumulated deficit		506,261,000		506,261,000		$ 421,543,000
Cash, cash equivalents, and short-term investments		$ 153,400,000		$ 153,400,000		185,500,000
Cash and cash equivalents, and investments, expected funding term for operating plan				12 months
At the Market Offering
Class of Stock [Line Items]
Aggregate authorized offering price	$ 75,000,000
Commission (percent)	3.00%
Issuance of common stock (in shares)		389,600		1,802,651
Offering price per share (in dollars per share)		$ 25.56		$ 25.56
Proceeds from issuance of common stock, net of at-the-market offering commissions				$ 38,200,000
Proceeds from issuance of common stock, net of commissions and offering costs		$ 9,600,000		38,800,000
Stock offering expenses				600,000
Stock offering expenses paid				$ 400,000		$ 200,000
Weighted Average | At the Market Offering
Class of Stock [Line Items]
Offering price per share (in dollars per share)		$ 22.17		$ 22.17

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) $ in Millions	Dec. 31, 2016USD ($)
Accounting Standards Update 2016-09 | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative charge top accumulated deficit for adoption of new accounting pronouncement	$ 0.1

In-Process Research and Devel29

In-Process Research and Development (Details) - USD ($)	Jun. 02, 2016	Jun. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	$ 2,000,000		$ 21,643,000	$ 10,296,000	$ 59,357,000	$ 37,851,000
Payment for acquisition of in-process research and development	1,800,000	$ 100,000			100,000	1,800,000
Holdback related to acquisition of in-process research and development	100,000				0	$ 200,000
Botulinum Toxin Research Associates, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued milestone obligations	$ 16,000,000		$ 16,000,000		$ 16,000,000

Medicis Settlement - Additional

Medicis Settlement - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2012	Sep. 30, 2017	Dec. 31, 2014	Dec. 31, 2013
Medicis Pharmaceutical Corporation
Settlement And Termination [Line Items]
Settlement consideration payable	$ 25
Upfront payment paid	7
Medicis Pharmaceutical Corporation | Proceeds Sharing Arrangement
Settlement And Termination [Line Items]
Settlement agreement, payable	$ 14
Settlement payment			$ 7.1	$ 6.9
Medicis Pharmaceutical Corporation | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Derivative liability for the Product Approval Payment		$ 2.2
Remaining contractual term (in years)		2 years 9 months
Risk-free interest rate		1.58%
Fair value assumptions, credit risk adjustment (percent)		7.00%
Valeant Pharmaceuticals International, Inc. | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Accrued milestone obligations		$ 4

Cash Equivalents and Investme31

Cash Equivalents and Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 152,640	$ 182,710
Gross unrealized gain	0	5
Gross unrealized loss	(43)	(50)
Available-for-sale securities, fair value	152,597	182,665
Cash equivalents
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, fair value	55,480	60,639
Short-term investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, fair value	97,117	122,026
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	55,480	60,639
Gross unrealized gain	0	0
Gross unrealized loss	0	0
Available-for-sale securities, fair value	55,480	60,639
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	81,210	81,103
Gross unrealized gain	0	4
Gross unrealized loss	(35)	(28)
Available-for-sale securities, fair value	81,175	81,079
U.S. government agency obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	15,950	40,968
Gross unrealized gain	0	1
Gross unrealized loss	(8)	(22)
Available-for-sale securities, fair value	$ 15,942	$ 40,947

Cash Equivalents and Investme32

Cash Equivalents and Investments - Related Party Transactions (Details) - USD ($) shares in Millions, $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Cash, cash equivalents, and short-term investments	$ 153.4	$ 185.5
J.P. Morgan Securities LLC [Member]
Related Party Transaction [Line Items]
Cash, cash equivalents, and short-term investments, fair value	$ 75.4	$ 86
J.P. Morgan Chase & Co. and Wholly Owned Subsidiaries [Member]
Related Party Transaction [Line Items]
Outstanding common stock held by related parties (shares)	3.5
Outstanding common stock held by related parties (percent)	11.40%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - Recurring - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 152,597	$ 182,665
Total liabilities measured at fair value	2,233	2,022
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	55,480	60,639
U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	81,175	81,079
U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	15,942	40,947
Derivative liability associated with Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	2,233	2,022
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	136,655	141,718
Total liabilities measured at fair value	0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	55,480	60,639
Level 1 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	81,175	81,079
Level 1 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 1 | Derivative liability associated with Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	15,942	40,947
Total liabilities measured at fair value	0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	15,942	40,947
Level 2 | Derivative liability associated with Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	2,233	2,022
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Derivative liability associated with Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$ 2,233	$ 2,022

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) - Derivative liability associated with Medicis settlement $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2016	$ 2,022
Change in fair value	211
Fair value as of September 30, 2017	$ 2,233

Notes Payable and Financing O35

Notes Payable and Financing Obligations - Essex Capital Notes (Detail) - Essex Notes - USD ($) $ in Millions	1 Months Ended
	May 31, 2017	Jun. 30, 2015	Apr. 30, 2015	Feb. 28, 2015	May 31, 2014	Jan. 31, 2014	Dec. 17, 2014	Dec. 20, 2013
Debt Instrument [Line Items]
Secured promissory notes, able to borrow, maximum								$ 10.8
Proceeds from loan and lease agreement						$ 5
Settlement of outstanding loan balance					$ 1.1
Lease period			3 years		3 years
Percentage of original purchase amount of asset at end of lease		10.00%			10.00%
Notes payable							$ 3.9
Shares available for purchase under common stock warrants (in shares)							44,753
Equipment purchased by third party, increase during period				$ 0.1
Equipment purchased by third party			$ 9.8
Purchase of equipment sold and leased back	$ 0.1	$ 1.1

Notes Payable and Financing O36

Notes Payable and Financing Obligations - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Debt Disclosure [Abstract]
2,017	$ 948
2,018	949
Total payments	$ 1,897

Interest Expense - Summary of I

Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Other Income and Expenses [Abstract]
Cash related interest expense	$ 63	$ 158	$ 259	$ 542
Non-cash Interest Expense [Abstract]
Effective interest on financing obligations	62	98	217	315
Non-cash effective interest expense	(21)	0	(37)	0
Non-cash interest expense	41	98	180	315
Total interest expense	$ 104	$ 256	$ 439	$ 857

Loss on Impairment (Details)

Loss on Impairment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Loss on impairment	$ 0	$ 0	$ 0	$ 1,949
Long-lived assets	11,500		11,500		$ 10,585
Fill/Finish Line
Property, Plant and Equipment [Line Items]
Long-lived assets	$ 5,100		$ 5,100

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Oct. 31, 2016	Feb. 28, 2014	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jan. 31, 2017	Jun. 02, 2016
Loss Contingencies [Line Items]
Extended term of lease		36 months
Rent expense			$ 1,300,000	$ 1,300,000	$ 4,000,000	$ 2,600,000
Purchase commitments			1,200,000		1,200,000
Valeant Pharmaceuticals International, Inc. | Product Approval Payment Derivative
Loss Contingencies [Line Items]
Accrued milestone obligations			4,000,000		4,000,000
Botulinum Toxin Research Associates, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations			16,000,000		16,000,000			$ 16,000,000
BioSentinel, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations			300,000		$ 300,000
City of Warren Police and Fire Retirement System | Settled Litigation
Loss Contingencies [Line Items]
Litigation settlement amount	$ 6,400,000
City of Warren Police and Fire Retirement System | Pending Litigation
Loss Contingencies [Line Items]
Loss contingency accrual	6,400,000
Amount paid for litigation settlement included in Restricted Cash							$ (500,000)
Insurance Company | City of Warren Police and Fire Retirement System | Settled Litigation
Loss Contingencies [Line Items]
Amount of litigation settlement covered by insurance policies	$ 5,900,000
Insurance Company | City of Warren Police and Fire Retirement System | Pending Litigation
Loss Contingencies [Line Items]
Amount of litigation settlement covered by insurance policies			$ 5,900,000

Commitments and Contingencies40

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 1,350
2,018	5,578
2,019	5,763
2,020	5,947
2021 and thereafter	20,644
Total payments	$ 39,282

Stockholders' Equity - Converti

Stockholders' Equity - Convertible Preferred Stock (Details) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Equity [Abstract]
Convertible preferred stock authorized (shares)	5,000,000	5,000,000,000
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 1
Convertible preferred stock outstanding (shares)	0	0
Convertible preferred stock issued (shares)	0	0

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - Common Stock - $ / shares	1 Months Ended
	Jul. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Shares available for purchase under common stock warrants (in shares)		41,595	61,595
Shares issuable under warrants (in shares)	20,000
Shares issued upon exercise of warrant (shares)	9,388
Warrant exercise price per share (in USD per share)	$ 14.40

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Plan Additional Information (Details) - shares	Jan. 01, 2017	Sep. 30, 2017
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	4.00%
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)		35,000
Common Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares outstanding increase during period (in shares)	1,145,958
Shares underlying stock options granted (in shares)		868,625
Shares available for issuance (in shares)		911,380
Common Stock | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance (in shares)		288,867
Employee Stock | 2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	1.00%
Common stock shares outstanding increase during period (in shares)	286,489
Shares available for issuance (in shares)		931,181
Restricted Stock Award | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share granted under restricted stock awards (shares)		310,575
Restricted Stock Award | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share granted under restricted stock awards (shares)		95,000

Stockholders' Equity - Stock 44

Stockholders' Equity - Stock Option Plan Fair Value Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	6 years	6 years	6 years
Expected volatility percentage	66.60%	64.20%	67.80%	61.60%
Risk-free interest rate	2.00%	1.20%	2.10%	1.40%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Non-employee Stock Options | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	8 years 11 months	7 years 2 months	8 years 11 months	7 years 5 months 15 days
Expected volatility percentage	68.10%	66.50%	68.60%	69.70%
Risk-free interest rate	2.20%	1.40%	2.20%	1.50%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Employee Stock | 2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
Expected volatility percentage	46.60%	80.90%	59.10%	72.00%
Risk-free interest rate	1.10%	0.40%	0.90%	0.40%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%

Stockholders' Equity - Stock 45

Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$ 3,146	$ 2,755	$ 9,820	$ 8,984
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	1,534	1,124	4,341	4,325
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$ 1,612	$ 1,631	$ 5,479	$ 4,659

Net Loss per Share Attributab46

Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Net loss attributable to common stockholders, basic and diluted	$ (30,651)	$ (17,978)	$ (84,680)	$ (62,468)
Net loss per share attributable to common stockholders, basic and diluted (in USD per share)	$ (1.01)	$ (0.64)	$ (2.86)	$ (2.22)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	30,270,260	28,160,458	29,623,805	28,085,541

Net Loss per Share Attributab47

Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	3,381,927	2,843,580
Outstanding common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	41,595	61,595
Unvested restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	640,931	327,899
Shares expected to be purchased on December 31 under the 2014 ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	14,778	11,643

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	1 Months Ended
	Oct. 31, 2017USD ($)
Revance International Limited | Subsequent Event
Subsequent Event [Line Items]
Transfer of rights to certain intellectual property	$ 42